Clinical Fellowships
Alnylam Pharmaceuticals funds U.S. academic fellowships to advance physician training and research in ATTR amyloidosis through multidisciplinary clinical programs.
Funder: Alnylam Pharmaceuticals
Due Dates: August 28, 2026 (Clinical Fellowships application)
Funding Amounts: Up to $95,000 per one-year fellowship; funds cover fellow salary and benefits only.
Summary: Supports U.S. academic institutions in advancing physician training and research in Transthyretin (ATTR) Amyloidosis through multidisciplinary clinical fellowship programs.
Key Information: Institutions must have an ACGME-accredited Cardiology Fellowship and cannot apply as individuals.
Description
Alnylam Pharmaceuticals Clinical Fellowships provide funding to U.S. academic institutions to support educational clinical programs aimed at mentoring and advancing physician training in the diagnosis, treatment, and research of Transthyretin (ATTR) Amyloidosis. The program is designed to foster multidisciplinary collaboration, enhance early recognition of ATTR, optimize treatment pathways, and accelerate the translation of emerging science into high-quality, patient-centered care. Funding is awarded directly to institutions, not individuals, and must be used exclusively for fellow salary and benefits.
